Profiles of multidrug resistance protein-1 in the peripheral blood mononuclear cells of patients with refractory epilepsy

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Ban, Jae Jun ^a,b   Jung, Keun Hwa ^a,b   Chu, Kon ^a,b   Lee, Soon Tae ^a,b   Jeon, Daejong ^c   Park, Kyung Il ^d   Moon, Hye Jin ^a   Kim, Hyeyun ^e   Kim, Sunghun ^f   Lee, Sang Kun ^a,b   Roh, Jae Kyu ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^d Inje University   (South Korea)

^e Catholic Kwandong University   (South Korea)

^f Gangwon National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN 1; OXCARBAZEPINE; PHENOBARBITAL; PREGABALIN; TOPIRAMATE; VALPROIC ACID; MULTIDRUG RESISTANCE PROTEIN;

ADULT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FUNCTION; REFRACTORY PERIOD; SEIZURE FREE EPILEPSY; TEMPORAL LOBE EPILEPSY; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; CHEMISTRY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; PATHOPHYSIOLOGY; PROGNOSIS; TREATMENT FAILURE;

ADULT; ANTICONVULSANTS; CASE-CONTROL STUDIES; DRUG RESISTANCE, MULTIPLE; EPILEPSY; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; P-GLYCOPROTEIN; PROGNOSIS; PROTEIN CONFORMATION; TREATMENT FAILURE; YOUNG ADULT;

EID: 84861012463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036985     Document Type: Article

References (30)

1. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA, (2007) Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 62: 382-389.
2. Gros P, Ben Neriah YB, Croop JM, Housman DE, (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728-731.
3. Fromm MF, (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423-429.
4. Schinkel AH, Jonker JW, (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3-29.
5. Loscher W, Potschka H, (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76: 22-76.
6. Robey RW, Lazarowski A, Bates SE, (2008) P-glycoprotein-a clinical target in drug-refractory epilepsy? Mol Pharmacol 73: 1343-1346.
7. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal-Bianco A, et al. (2004) Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63: 1087-1089.
8. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, et al. (2001) Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42: 1501-1506.
9. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, et al. (2007) ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 48 (Suppl 5): 140-149.
10. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, et al. (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36: 1-6.
11. Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Arguelles A, et al. (2000) Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 67: 40-48.
12. Grude P, Boleslawski E, Conti F, Chouzenoux S, Calmus Y, (2002) MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation. Transplantation 73: 1824-1828.
13. Senent L, Jarque I, Martin G, Sempere A, Gonzalez-Garcia Y, et al. (1998) P-glycoprotein expression and prognostic value in acute myeloid leukemia. Haematologica 83: 783-787.
14. Tsujimura S, Saito K, Nakayamada S, Tanaka Y, (2007) Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus. Histol Histopathol 22: 465-468.
15. Mohr S, Liew CC, (2007) The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol Med 13: 422-432.
16. Turriziani O, Gianotti N, Falasca F, Boni A, Vestri AR, et al. (2008) Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J Med Virol 80: 766-771.
17. Karsten SL, Kudo LC, Bragin AJ, (2011) Use of peripheral blood transcriptome biomarkers for epilepsy prediction. Neurosci Lett 497: 213-217.
18. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600.
19. Beleza P, (2009) Refractory epilepsy: a clinically oriented review. Eur Neurol 62: 65-71.
20. Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, et al. (2010) Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm 7: 642-651.
21. Mechetner EB, Schott B, Morse BS, Stein WD, Druley T, et al. (1997) P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci U S A 94: 12908-12913.
22. Druley TE, Stein WD, Ruth A, Roninson IB, (2001) P-glycoprotein-mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation. Biochemistry 40: 4323-4331.
23. Vilas-Boas V, Silva R, Gaio AR, Martins AM, Lima SC, et al. (2011) P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. Cytometry A 79: 912-919.
24. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, et al. (2009) Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51.
25. van Vliet EA, Edelbroek PM, Gorter JA, (2010) Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats. Epilepsia 51: 362-370.
26. Luna-Tortos C, Fedrowitz M, Loscher W, (2008) Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55: 1364-1375.
27. Zhang C, Kwan P, Zuo Z, Baum L, (2011) The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev.
28. Parfenova H, Leffler CW, Tcheranova D, Basuroy S, Zimmermann A, (2010) Epileptic seizures increase circulating endothelial cells in peripheral blood as early indicators of cerebral vascular damage. Am J Physiol Heart Circ Physiol 298: H1687-1698.
29. Langer O, Bauer M, Hammers A, Karch R, Pataraia E, et al. (2007) Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 48: 1774-1784.
30. Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, et al. (2007) Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab 27: 424-433.